Risk factors and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in haematology department: A 10-year retrospective study

Yuan, Fangfang; Li, Minghui; Wang, Xiaokun; Fu, Yuewen

doi:10.1016/j.jgar.2024.03.018

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Preprint1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Rapid susceptibility of Carbapenem resistant Pseudomonas aeruginosa and its resistance gene to non-thermal plasma treatment in a batch reactor

Mosaka,

Unuofin,

Daramola

et al. 2024

Journal of Water Process Engineering

View full text Add to dashboard Cite

Rapid susceptibility of Carbapenem resistant Pseudomonas aeruginosa and its resistance gene to non-thermal plasma treatment in a batch reactor

Mosaka,

Unuofin,

Daramola

et al. 2024

Journal of Water Process Engineering

View full text Add to dashboard Cite

Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Aldardeer,

Labban,

Alhuthil

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Aldardeer,

Labban,

Alhuthil

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbapenem β-lactam (NCBL) agents. Thus, this study aims to assess the effectiveness of traditional NCBL compared to Noval β-lactam agents (NVL) for treating non-carbapenem β-lactam -susceptible CRPA. Methods A single-center retrospective cohort study was conducted between January 2016 and December 2022. The study included adult patients 18 years and older with infection due to CRPA who were treated based on microbiology sensitivity with traditional NCBL or NVL for more than 48 hours. The primary outcome was 30-day mortality. Results 124 patients were included: 98 (79%) in the NCBL group and 26 (20.9%) in the NVL group. 78 (62.9%) patients were male. The median (interquartile range (IQR)) age of included patients was 64 (45, 77) years. A total of 84 (67.7%) patients were critically ill, with an overall median (IQR) APACHE II score of 18 (13.5, 23). The rates of 30-day mortality in NCBL and NVL groups were 41 (41.8%) and 12 (46.2%), respectively; P = 0.692. Conclusion In patients with CRPA infections susceptible to traditional NCBL, there was no statistical significant difference in 30-day mortality among patients who were treated with traditional NCBL compared with NVL. Further studies with larger sample sizes are needed to confirm these findings.

show abstract

Risk factors and mortality of carbapenem-resistant Pseudomonas aeruginosa bloodstream infection in haematology department: A 10-year retrospective study

Cited by 4 publications

References 26 publications

Rapid susceptibility of Carbapenem resistant Pseudomonas aeruginosa and its resistance gene to non-thermal plasma treatment in a batch reactor

Rapid susceptibility of Carbapenem resistant Pseudomonas aeruginosa and its resistance gene to non-thermal plasma treatment in a batch reactor

Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Contact Info

Product

Resources

About